GENB
Generate Biomedicines, Inc. Common Stock
NASDAQ: GENB · HEALTHCARE · BIOTECHNOLOGY
$12.63
+2.02% today
Updated 2026-04-30
Market cap
$1.59B
P/E ratio
—
P/S ratio
49.75x
EPS (TTM)
$-2.18
Dividend yield
—
52W range
$11 – $16
Volume
0.6M
Generate Biomedicines, Inc. Common Stock (GENB) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2024 | 2025 |
|---|---|---|
| Revenue | $20.46M | $31.89M |
| Revenue growth (YoY) | — | +55.9% |
| Cost of revenue | — | — |
| Gross profit | $20.46M | $31.89M |
| Gross margin | 100.0% | 100.0% |
| R&D | $175.31M | $224.70M |
| SG&A | $42.09M | $42.26M |
| Operating income | $-196.94M | $-235.06M |
| Operating margin | -962.6% | -737.0% |
| EBITDA | $-163.71M | $-208.49M |
| EBITDA margin | -800.2% | -653.7% |
| EBIT | $-179.05M | $-221.67M |
| Interest expense | $2.12M | $1.14M |
| Income tax | — | — |
| Effective tax rate | 0.0% | 0.0% |
| Net income | $-173.77M | $-203.15M |
| Net income growth (YoY) | — | -16.9% |
| Profit margin | -849.4% | -637.0% |